Back to Journals » Vascular Health and Risk Management » Volume 8

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus-eluting stent in a consecutive cohort of patients at a tertiary medical center

Authors Shammas N, Shammas, Nader, Jerin M, Mrad, Marogil, Henn, Dvorak, Chintalapani, Meriner

Received 22 January 2012

Accepted for publication 9 March 2012

Published 11 April 2012 Volume 2012:8 Pages 205—211


Review by Single-blind

Peer reviewer comments 3

Nicolas W Shammas, Gail A Shammas, Elie Nader, Michael Jerin, Luay Mrad, Peter Marogil, Courtney Henn, Alex Dvorak, Archana Chintalapani, Susan Meriner
Midwest Cardiovascular Research Foundation, Davenport, IA, USA

Background: In this study we compared the outcomes of the everolimus-eluting stent (EES) versus the zotarolimus-eluting stent (ZES) in patients treated at a tertiary medical center, with up to one year of follow-up.
Methods: Unselected consecutive patients were retrospectively recruited following stenting with the ZES (n = 197) or EES (n = 190). The first 100 consecutive patients in each cohort underwent syntax scoring. The primary endpoint of the study was target vessel failure, defined as the combined endpoint of cardiac death, non-fatal myocardial infarction, or target vessel revascularization. Secondary endpoints included target lesion revascularization, target lesion failure, acute stent thrombosis, total death, cardiac death, and non-fatal myocardial infarction.
Results: The two groups were similar, including for Syntax scores (19.6 ± 12.8 versus 20.6 ± 13.6), number of stents per patient (2.9 ± 1.9 versus 2.9 ± 2.1), and cardiovascular risk factors. By one year, the primary outcome occurred in 20.8% EES versus 26.7% ZES (P = 0.19) patients. The secondary endpoints were as follows: target lesion revascularization (8.9% versus 20.6%, P = 0.003), target vessel revascularization (18.9% versus 25.6%, P = 0.142), definite and probable stent thrombosis (0% versus 2.5%), non-fatal myocardial infarction (2.7% versus 3.6%), and mortality (3.2% versus 5.1%) for the EES versus the ZES, respectively.
Conclusion: EES had similar target vessel failure to ZES, but superior target lesion revascularization and target lesion failure at one year of follow-up in an unselected cohort of patients.

Keywords: coronary stent, drug eluting stent, zotarolimus, everolimus, outcome, target lesion revascularization, stent thrombosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Ten-year outcome of intraoperative treatment of atrial fibrillation using radiofrequency ablation

Boulad N, Shammas NW, Early G, Roberts S, Shammas GA, Hu YL, Park H, Jerin M

Therapeutics and Clinical Risk Management 2017, 13:1233-1237

Published Date: 19 September 2017

Predictors of common femoral artery access site complications in patients on oral anticoagulants and undergoing a coronary procedure

Shammas NW, Shammas GA, Jones-Miller S, Gumpert MR, Gumpert MJ, Harb C, Chammas MZ, Shammas WJ, Khalafallah RA, Barzgari A, Bou Dargham B, Daher GE, Rachwan RJ, Shammas AN

Therapeutics and Clinical Risk Management 2017, 13:401-406

Published Date: 30 March 2017

Sex differences in long-term outcomes of coronary patients treated with drug-eluting stents at a tertiary medical center

Shammas NW, Shammas GA, Jerin M, Sharis P

Vascular Health and Risk Management 2014, 10:563-568

Published Date: 9 September 2014

Readers of this article also read:

Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease

Anakwue RC, Onwubere BJ, Ikeh V, Anisiuba B, Ike S, Anakwue AC

Therapeutics and Clinical Risk Management 2015, 11:189-200

Published Date: 5 February 2015

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women

Prasad M, Reriani M, Khosla S, Gössl M, Lennon R, Gulati R, Prasad A, Lerman LO, Lerman A

Vascular Health and Risk Management 2014, 10:533-538

Published Date: 26 August 2014

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty

Levitan B, Yuan Z, Turpie AGG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM

Vascular Health and Risk Management 2014, 10:157-167

Published Date: 26 March 2014

Effects of low-fat dairy intake on blood pressure, endothelial function, and lipoprotein lipids in subjects with prehypertension or stage 1 hypertension

Maki KC, Rains TM, Schild AL, Dicklin MR, Park KM, Lawless AL, Kelley KM

Vascular Health and Risk Management 2013, 9:369-379

Published Date: 23 July 2013

Ezetimibe therapy: mechanism of action and clinical update

Phan BAP, Dayspring TD, Toth PP

Vascular Health and Risk Management 2012, 8:415-427

Published Date: 3 July 2012

HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men

Nikolaos Papanas, Paschalis Steiropoulos, Evangelia Nena, et al

Vascular Health and Risk Management 2009, 5:751-756

Published Date: 8 September 2009